Literature DB >> 29296884

Changes in bone marrow innate lymphoid cell subsets in monoclonal gammopathy: target for IMiD therapy.

Jithendra Kini Bailur1, Sameet Mehta2, Lin Zhang1, Natalia Neparidze1, Terri Parker1, Noffar Bar1, Tara Anderson1, Mina L Xu3, Kavita M Dhodapkar4, Madhav V Dhodapkar1,5.   

Abstract

Altered number, subset composition, and function of bone marrow innate lymphoid cells are early events in monoclonal gammopathies.Pomalidomide therapy leads to reduction in Ikzf1 and Ikzf3 and enhanced human innate lymphoid cell function in vivo.

Entities:  

Year:  2017        PMID： 29296884      PMCID： PMC5729633          DOI： 10.1182/bloodadvances.2017012732

Source DB:  PubMed          Journal:  Blood Adv        ISSN： 2473-9529


  25 in total

1.  Peripheral natural killer cell maturation depends on the transcription factor Aiolos.

Authors:  Melissa L Holmes; Nicholas D Huntington; Rebecca P L Thong; Jason Brady; Yoshihiro Hayakawa; Christopher E Andoniou; Peter Fleming; Wei Shi; Gordon K Smyth; Mariapia A Degli-Esposti; Gabrielle T Belz; Axel Kallies; Sebastian Carotta; Mark J Smyth; Stephen L Nutt
Journal:  EMBO J       Date:  2014-10-15       Impact factor: 11.598

2.  CD127+ innate lymphoid cells are dysregulated in treatment naïve acute myeloid leukemia patients at diagnosis.

Authors:  Sara Trabanelli; Antonio Curti; Mariangela Lecciso; Bérengère Salomé; Carsten Riether; Adrian Ochsenbein; Pedro Romero; Camilla Jandus
Journal:  Haematologica       Date:  2015-02-20       Impact factor: 9.941

Review 3.  MGUS to myeloma: a mysterious gammopathy of underexplored significance.

Authors:  Madhav V Dhodapkar
Journal:  Blood       Date:  2016-10-13       Impact factor: 22.113

Review 4.  Innate lymphoid cells as regulators of immunity, inflammation and tissue homeostasis.

Authors:  Christoph S N Klose; David Artis
Journal:  Nat Immunol       Date:  2016-06-21       Impact factor: 25.606

5.  Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets.

Authors:  Kartik Sehgal; Rituparna Das; Lin Zhang; Rakesh Verma; Yanhong Deng; Mehmet Kocoglu; Juan Vasquez; Srinivas Koduru; Yan Ren; Maria Wang; Suzana Couto; Mike Breider; Donna Hansel; Stuart Seropian; Dennis Cooper; Anjan Thakurta; Xiaopan Yao; Kavita M Dhodapkar; Madhav V Dhodapkar
Journal:  Blood       Date:  2015-04-13       Impact factor: 22.113

6.  Interleukin-7 Availability Is Maintained by a Hematopoietic Cytokine Sink Comprising Innate Lymphoid Cells and T Cells.

Authors:  Christopher E Martin; Darina S Spasova; Kwesi Frimpong-Boateng; Hee-Ok Kim; Minji Lee; Kwang Soon Kim; Charles D Surh
Journal:  Immunity       Date:  2017-07-18       Impact factor: 31.745

7.  Cancer Immunosurveillance by Tissue-Resident Innate Lymphoid Cells and Innate-like T Cells.

Authors:  Saïda Dadi; Sagar Chhangawala; Benjamin M Whitlock; Ruth A Franklin; Chong T Luo; Soyoung A Oh; Ahmed Toure; Yuri Pritykin; Morgan Huse; Christina S Leslie; Ming O Li
Journal:  Cell       Date:  2016-01-21       Impact factor: 41.582

8.  Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide.

Authors:  A Lopez-Girona; D Mendy; T Ito; K Miller; A K Gandhi; J Kang; S Karasawa; G Carmel; P Jackson; M Abbasian; A Mahmoudi; B Cathers; E Rychak; S Gaidarova; R Chen; P H Schafer; H Handa; T O Daniel; J F Evans; R Chopra
Journal:  Leukemia       Date:  2012-05-03       Impact factor: 11.528

9.  PD-1 regulates KLRG1+ group 2 innate lymphoid cells.

Authors:  Samuel Taylor; Yuefeng Huang; Grace Mallett; Chaido Stathopoulou; Tania C Felizardo; Ming-An Sun; Evelyn L Martin; Nathaniel Zhu; Emma L Woodward; Martina S Elias; Jonathan Scott; Nick J Reynolds; William E Paul; Daniel H Fowler; Shoba Amarnath
Journal:  J Exp Med       Date:  2017-05-10       Impact factor: 14.307

10.  Human ILC1: To Be or Not to Be.

Authors:  Jochem H Bernink; Jenny Mjösberg; Hergen Spits
Journal:  Immunity       Date:  2017-05-16       Impact factor: 31.745
View more
  15 in total

1.  Early alterations in stem-like/resident T cells, innate and myeloid cells in the bone marrow in preneoplastic gammopathy.

Authors:  Jithendra Kini Bailur; Samuel S McCachren; Deon B Doxie; Mahesh Shrestha; Katherine Pendleton; Ajay K Nooka; Natalia Neparidze; Terri L Parker; Noffar Bar; Jonathan L Kaufman; Craig C Hofmeister; Lawrence H Boise; Sagar Lonial; Melissa L Kemp; Kavita M Dhodapkar; Madhav V Dhodapkar
Journal:  JCI Insight       Date:  2019-04-23

2.  Differential effects of PD-L1 versus PD-1 blockade on myeloid inflammation in human cancer.

Authors:  Noffar Bar; Federica Costa; Rituparna Das; Alyssa Duffy; Mehmet Samur; Samuel McCachren; Scott N Gettinger; Natalia Neparidze; Terri L Parker; Jithendra Kini Bailur; Katherine Pendleton; Richa Bajpai; Lin Zhang; Mina L Xu; Tara Anderson; Nicola Giuliani; Ajay Nooka; Hearn J Cho; Aparna Raval; Mala Shanmugam; Kavita M Dhodapkar; Madhav V Dhodapkar
Journal:  JCI Insight       Date:  2020-06-18

Review 3.  Harnessing Unconventional T Cells and Innate Lymphoid Cells to Prevent and Treat Hematological Malignancies: Prospects for New Immunotherapy.

Authors:  Alessandro Allegra; Marco Casciaro; Elena Lo Presti; Caterina Musolino; Sebastiano Gangemi
Journal:  Biomolecules       Date:  2022-05-27

Review 4.  Innate lymphoid cells and cancer.

Authors:  Nicolas Jacquelot; Cyril Seillet; Eric Vivier; Gabrielle T Belz
Journal:  Nat Immunol       Date:  2022-02-28       Impact factor: 31.250

Review 5.  Summary of the 2019 Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling.

Authors:  Sarah A Holstein; Alan Howard; David Avigan; Manisha Bhutani; Adam D Cohen; Luciano J Costa; Madhav V Dhodapkar; Francesca Gay; Nicole Gormley; Damian J Green; Jens Hillengass; Neha Korde; Zihai Li; Sham Mailankody; Paola Neri; Samir Parekh; Marcelo C Pasquini; Noemi Puig; G David Roodman; Mehmet Kemal Samur; Nina Shah; Urvi A Shah; Qian Shi; Andrew Spencer; Vera J Suman; Saad Z Usmani; Philip L McCarthy
Journal:  Biol Blood Marrow Transplant       Date:  2020-06-24       Impact factor: 5.742

Review 6.  Humanized Mouse Models for the Advancement of Innate Lymphoid Cell-Based Cancer Immunotherapies.

Authors:  Nina B Horowitz; Imran Mohammad; Uriel Y Moreno-Nieves; Ievgen Koliesnik; Quan Tran; John B Sunwoo
Journal:  Front Immunol       Date:  2021-04-22       Impact factor: 7.561

Review 7.  Checkpoint Inhibition in Myeloma: Opportunities and Challenges.

Authors:  Federica Costa; Rituparna Das; Jithendra Kini Bailur; Kavita Dhodapkar; Madhav V Dhodapkar
Journal:  Front Immunol       Date:  2018-09-26       Impact factor: 7.561

Review 8.  Moving Immunoprevention Beyond Virally Mediated Malignancies: Do We Need to Link It to Early Detection?

Authors:  Madhav V Dhodapkar; Kavita M Dhodapkar
Journal:  Front Immunol       Date:  2019-10-10       Impact factor: 7.561

9.  Risk-associated alterations in marrow T cells in pediatric leukemia.

Authors:  Jithendra Kini Bailur; Samuel S McCachren; Katherine Pendleton; Juan C Vasquez; Hong Seo Lim; Alyssa Duffy; Deon B Doxie; Akhilesh Kaushal; Connor Foster; Deborah DeRyckere; Sharon Castellino; Melissa L Kemp; Peng Qiu; Madhav V Dhodapkar; Kavita M Dhodapkar
Journal:  JCI Insight       Date:  2020-08-20

Review 10.  Helper Innate Lymphoid Cells in Allogenic Hematopoietic Stem Cell Transplantation and Graft Versus Host Disease.

Authors:  Linda Quatrini; Nicola Tumino; Francesca Moretta; Francesca Besi; Paola Vacca; Lorenzo Moretta
Journal:  Front Immunol       Date:  2020-09-30       Impact factor: 7.561
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.